- Increases NeuPath clinic network to 15 clinics, plus minority ownership of 2 additional clinics
- NeuPath’s second clinic in Alberta
- Collaborative care model, including orthopedic surgeons and interventional pain care physicians
- NeuPath has also added a fluoroscopy suite in Hamilton
NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its wholly-owned subsidiary, HealthPointe Medical Centres Ltd. (“HealthPointe”), has entered into a partnership with Central Alberta Orthopedics (“CAO”), a leading provider of multidisciplinary care in musculoskeletal trauma and reconstructive surgery, to open an interdisciplinary pain institute in Red Deer, Alberta. The clinic is expected to be open to patients in May 2022 and ownership of the newly formed corporation is split 50/50 between HealthPointe and CAO.
“The journey for patients with musculoskeletal conditions usually involves requisitions for x-rays or MRIs, prescriptions for pain killers, referrals to physical therapists, and referrals to specialist physicians. Patients bounce around between each of these pathways, which can go on for years in some cases,” stated Grant Connelly, CEO of NeuPath. “This approach can also create unnecessary strain on the healthcare system. Given the unprecedented backlog for medical procedures created by the COVID-19 pandemic, it is critical that we identify solutions that reduce strain on the healthcare system and provide quicker access to the most appropriate care for patients. We believe working collaboratively with talented and respected groups like Central Alberta Orthopedics has the potential to improve access to care, shorten wait times, and produce better outcomes for patients, while also benefitting the broader healthcare system.”
“Through our years of providing care to patients in the Central Alberta region, we recognized a need for interdisciplinary pain care in the area,” commented Dr. Timothy Pearce, orthopedic surgeon and partner at CAO. “We look forward to being able fill a need for patients in the Central Zone, while also collaborating with a leading interdisciplinary pain care provider like HealthPointe.”
In addition, NeuPath is pleased to announce the Company has added a new clinic in Hamilton, Ontario. The new clinic has a fluoroscopy suite and the Company expects the clinic to be open to patients in February 2022.
“Our clinic network has grown to 15 clinics and, within our network, we currently have six fluoroscopy suites operational or under construction,” added Grant Connelly. “This is an important development for patients, as it allows our physicians to add services and better meet the needs of our patients.”
About NeuPath
NeuPath is a vertically integrated health care provider utilizing research, data-driven insights, technology, and interdisciplinary care to help restore function for patients impacted by chronic pain, spinal injuries, sport-related injuries, and concussions. With equity ownership in seventeen clinics in Ontario and Alberta, NeuPath is building out a large-scale network to better serve patients across Canada and the United States. NeuPath is focused on transforming the hope of a better life into the reality of a life more fully lived.
Forward-Looking Statements
This news release contains forward-looking statements. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future including, without limitation, the execution of the Company’s expansion strategy in 2022, including the timing of clinic openings, are forward-looking statements. These forward-looking statements reflect the current expectations or beliefs of the Company based on information currently available to the Company. Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Company. Factors that could cause actual results or events to differ materially from current expectations included in this news release include, among other things, the severity, duration and spread of the COVID-19 outbreak, as well as its direct and indirect impacts that the pandemic may have on the Company’s operations, adverse market conditions, risks associated with obtaining and maintaining the necessary governmental permits and licenses related to the business of the Company, increasing competition in the market and other risks generally inherent in the chronic pain, sports medicine, concussion and workplace health services markets. A comprehensive discussion of these and other risks and uncertainties can be found in the Company’s annual information form dated March 25, 2021 filed on SEDAR under the Company’s profile at www.sedar.com.
Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to their inherent uncertainty.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS THE RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005357/en/